Skip to main content

Aqua Bio Technology ASA: Sikkerhetsstudier av 6 produkter fra produktserien Balance & Vitality fullført og godkjent

Written by Customer Service on . Posted in Public Companies.

Det vises til børsmelding av 26 november 2020 vedrørende pågående sikkerhetsstudier for produktseriene Nordic Beauty og Balance & Vitality. ABT har mottatt bekreftelse på at de 6 første produktene fra Balance & Vitality serien har passert sikkerhetsstudier som EU krever gjennomført før kommersialisering. Resultatene for ytterligere 18 produkter forventes i løpet av januar i 2021, mens de siste 3 produktene som kompletterer serien forventes godkjent i løpet av Q1. Balance & Vitality vil være en komplett hudpleieserie med produkter i alle kategorier.Testene er utført hos Eurofins, som er verdens største innenfor testing av mat, miljø, medisin og kosmetikk og har 800 laboratorier i mer enn 50 forskjellige land.ABT forventer at produktserien Balance & Vitality er klar for distribusjon og salg første halvår 2021.For nærmere informasjon kontakt adm. direktør Espen Kvale, telefon 916 28 092.Aqua Bio Technology ASA (ABT) utvikler og kommersialiserer bærekraftig
bioteknologi for bruk i hudpleieprodukter. ABTs kosmetikkingredienser er svært
effektive og de representerer et naturlig alternativ til tradisjonelle
ingredienser for kosmetikkindustrien. ABT markedsfører og selger dessuten
naturlige hudpleieprodukter utviklet av partnere til konsumenter og
profesjonelle brukere. Aqua Bio Technology er notert på Euronext Expand.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.